Global Gene Therapy Market Size, Share

Industry Insights

[205+ Pages Report] We at Facts & Factors have recently published a report titled “Global Gene Therapy Market” that encompasses the spectacle of the market in an analytical and comprehensive manner. We at Facts & Factors estimate that the gene therapy market will be valued at USD 12.9 Billion in the year 2026 from an initial value of USD 2.7 Billion in the year 2020 at a CAGR value of 22.3%.

Market Overview

Gene therapy is a medical binomial that allows for the modification of a person’s genes in order to develop antibodies for treating or curating diseases. Gene therapies can work by employing several mechanisms such as replacing a disease-causing gene with a healthy variation of the gene or by inactivating a disease-causing gene that does not have the proper functionality. Additionally, a mechanism can include introducing a newly modified gene into the body for further eliminating a disease. The variety of gene therapies that are currently available are plasmid DNA, viral vectors, bacterial vectors, human gene-editing technology, and patient-derived cellular gene therapy products, to name a few.

Industry Growth Factors

The primary driving factors for the significant growth of the global gene therapy market are the increasing prevalence of cancer and other targeted disorders coupled with the rising availability of measures. Additionally, gene therapy is being granted several reimbursements from various insurance carriers which increases the revenue stream that can be generated for the market during the forecast period. Rising funding for gene therapy research coupled with the rising adoption of gene therapy therapeutics is expected to increase the footprint of the global gene therapy market during the forecast period. A dynamic competitive nature is expected to drive the market due to several initiatives that are undertaken by the key market players such as the biopharma companies.

The insurgence of the current pandemic is expected to create a positive impact on the global gene therapy market during the forecast period. The market is expected to increase in boundaries due to the added intervention of life-threatening diseases such as heart diseases, AIDS, cystic fibrosis, and age-related disorders. Rising investment in research and development activities is further expected to curate a larger market revenue for the global gene therapy market during the forecast period. However, high prices and irregular availability is expected to dim the market growth to a slower rate during the forecast period.

Segmentation Analysis

The global gene therapy market can be segmented into vectors, delivery methods, indications, and regions.

The global gene therapy market can be divided into viral and non-viral vectors on the basis of vectors. The segment pertaining to non-viral vectors is expected to witness the largest market share during the advent of the forecast owing to technological advancements for physicochemical approaches in materials such as lipid, naked DNA, chromosomes, plasmid, cationic polymers, and conjugate complexes to name a few. The global gene therapy market can be fragmented into in vivo and ex vivo on the basis of delivery mode. The ex vivo segment is expected to occupy the largest market share during the advent of the forecast owing to a safer mode of operation and easy deliverables to name a few. The global gene therapy market can be broken down into neurological diseases, cancer, Duchenne muscular dystrophy, hepatological diseases, and others on the basis of indication. The segment pertaining to cancer is expected to witness the largest market share during the advent forecast period owing to the rising approval of gene therapies for the treatment of cancer coupled with the increasing prevalence of hematologic cancers to name a few.

Regional Analysis

North America is expected to witness the largest market share during the forecast period in terms of global revenue contribution. The factors that contribute to the market dominance on a global scale can be attributed to the rising prevalence of chronic diseases coupled with a high and growing healthcare expenditure to name a few. Additionally, integration of advanced healthcare infrastructure coupled with readily available reimbursements measures are expected to increase the footprint of the gene therapy market in the region. Increasing key market players in the region coupled with favorable regulatory approval are expected to project the gene therapy market on a steadfast path during the forecast period.

Competitive Players

The key market participants for the global gene therapy market are REGENBIO, Inc., Oxford BioMedicaPlc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetics Technologies Corporation, Bluebird Bio, Inc., TaxusCardium Pharmaceutical Group, Inc., UniQure N.V., Shire Plc, Cellectis S.A., Sangamo Therapeutics, Inc., Gilead Lifesciences, Inc., and Shanghai Sunway Biotech Co. Ltd., among others.

By Vectors Segment Analysis

• Viral
  • Retroviral Vector
    • Gammaretroviral Vector
    • Lentiviral Vector
  • Adeno-Associated Vector
  • Other Viral Vectors
• Non-Viral
  • Oligonucleotides

By Delivery ModeSegment Analysis

• In Vivo
• Ex Vivo

By IndicationSegment Analysis

• Neurological Diseases
• Cancer
• Duchenne Muscular Dystrophy
• Hepatological Diseases
• Others

By Regional Segment Analysis

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of MEA